Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET STOCKHOLM, Oct. 25, 2023 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the company…